Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22927041 | 0.81 | RAPGEF4 (0.34) | GAAMAPTRAPGEF4 | |
| SCHEMBL3947356 | 0.80 | CYP3A4 (0.44) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL1755264 | 0.79 | RAPGEF4 (0.48) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL21727427 | 0.76 | RAPGEF4 (0.37) | ALOX15RAPGEF4 | |
| SCHEMBL16150965 | 0.76 | POLB (0.39) | CYP3A4ALDH1A1GAAMAPTAR | |
| SCHEMBL5355782 | 0.75 | PTGS2 (0.31) | PTGS2 | |
| SCHEMBL5355232 | 0.75 | ESR1 (0.48) | CYP3A4ALDH1A1GAAMAPTPTGS1 | |
| SCHEMBL3140759 | 0.75 | AGBL2 (0.32) | — | |
| SCHEMBL698408 | 0.75 | POLB (0.52) | CYP3A4ALDH1A1GAAMAPTAR | |
| SCHEMBL16703818 | 0.75 | RAPGEF4 (0.36) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169955-B2 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | NIHON NOHYAKU CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | NIHON NOHYAKU CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1253128-A1 | PERFLUOROISOPROPYLBENZENE DERIVATIVES | Nihon Nohyaku Co., Ltd. (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187233-A1 | PERFLUOROISOPROPYBENZENE DERIVATIVE | AFF1, CBR1, RER1 | CYP3A4 223/4885CHRM1 302/4885ALOX15 993/4885 |
| US-20050113567-A1 | Perfluoroisopropylbenzene derivative | FFAR3, CBR3, HCAR3 | CYP3A4 197/4885CHRM1 209/4885ALOX15 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.